Christian Kappeler
Berlin, BE 13353, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2023
Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
Journal: Targeted oncology
Published: March 17, 2023
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: June 16, 2021
Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Journal: Journal of gastroenterology and hepatology
Published: May 22, 2019
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Journal: The New England journal of medicine
Published: February 15, 2019
Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Journal: The oncologist
Published: January 24, 2019
Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 23, 2018
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Journal: The oncologist
Published: February 05, 2018
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Journal: Endocrine-related cancer
Published: September 16, 2015
Sorafenib for patients with differentiated thyroid cancer--authors' reply.
Journal: Lancet (London, England)
Published: February 24, 2015
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 09, 2014
Last Updated: 09/26/2026